Towa Pharmaceutical Co., Ltd.
TWAPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $122,453,368 | $119,281,907 | $179,741,684 | $188,566,347 |
| - Cash | $49,576,000 | $35,015,000 | $45,471,000 | $29,252,000 |
| + Debt | $236,263,000 | $237,894,000 | $230,983,000 | $223,479,000 |
| Enterprise Value | $309,140,368 | $322,160,907 | $365,253,684 | $382,793,347 |
| Revenue | $441,611 | $65,149,000 | $65,857,000 | $70,333,000 |
| % Growth | -99.3% | -1.1% | -6.4% | – |
| Gross Profit | $159,070 | $23,675,000 | $23,985,000 | $25,830,000 |
| % Margin | 36% | 36.3% | 36.4% | 36.7% |
| EBITDA | $96,391 | $10,456,000 | $10,968,000 | $12,260,000 |
| % Margin | 21.8% | 16% | 16.7% | 17.4% |
| Net Income | $38,539 | $2,513,000 | $4,362,000 | $8,069,000 |
| % Margin | 8.7% | 3.9% | 6.6% | 11.5% |
| EPS Diluted | 0.78 | 51.05 | 88.61 | 163.92 |
| % Growth | -98.5% | -42.4% | -45.9% | – |
| Operating Cash Flow | $55,432 | $5,892,000 | $17,706,000 | -$2,959,000 |
| Capital Expenditures | -$56,939 | -$4,380,000 | -$6,827,000 | -$10,341,000 |
| Free Cash Flow | -$1,507 | $1,512,000 | $10,879,000 | -$13,300,000 |